Design and selection of DMP 850 and DMP 851: the next generation of cyclic urea HIV protease inhibitors

@article{Rodgers1998DesignAS,
  title={Design and selection of DMP 850 and DMP 851: the next generation of cyclic urea HIV protease inhibitors},
  author={Rodgers and Lam and Johnson and Wang and Ko and Seitz and Trainor and Anderson and Klabe and Bacheler and Cordova and Garber and Reid and Wright and Chang and Erickson-Viitanen},
  journal={Chemistry & biology},
  year={1998},
  volume={5 11},
  pages={
          R312
        }
}
Abstract Background: Recent clinical trials have demonstrated that HIV protease inhibitors are useful in the treatment of AIDS. It is necessary, however, to use HIV protease inhibitors in combination with other antiviral agents to inhibit the development of resistance. The daunting ability of the virus to rapidly generate resistant mutants suggests that there is an ongoing need for new HIV protease inhibitors with superior pharmacokinetic and efficacy profiles. In our attempts to design and… Expand
27 Citations
Development of HIV protease inhibitors: a survey.
  • S. Ren, E. Lien
  • Biology, Medicine
  • Progress in drug research. Fortschritte der Arzneimittelforschung. Progres des recherches pharmaceutiques
  • 2001
Resistance Profiles of Cyclic and Linear Inhibitors of HIV-1 Protease
Discovery and clinical development of HIV-1 protease inhibitors.
The next generation of HIV/AIDS drugs: novel and developmental antiHIV drugs and targets
  • J. Turpin
  • Medicine
  • Expert review of anti-infective therapy
  • 2003
Interpreting trends in the binding of cyclic ureas to HIV-1 protease.
...
1
2
3
...

References

SHOWING 1-10 OF 24 REFERENCES
L-735,524: an orally bioavailable human immunodeficiency virus type 1 protease inhibitor.
  • J. Vacca, B. Dorsey, +7 authors E. Roth
  • Biology, Medicine
  • Proceedings of the National Academy of Sciences of the United States of America
  • 1994
ABT-538 is a potent inhibitor of human immunodeficiency virus protease and has high oral bioavailability in humans.
  • D. Kempf, K. Marsh, +7 authors X. Kong
  • Biology, Medicine
  • Proceedings of the National Academy of Sciences of the United States of America
  • 1995
Human immunodeficiency virus type 1 viral background plays a major role in development of resistance to protease inhibitors.
  • R. Rose, Y. F. Gong, +6 authors P. Lin
  • Biology, Medicine
  • Proceedings of the National Academy of Sciences of the United States of America
  • 1996
...
1
2
3
...